Your browser doesn't support javascript.
loading
Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
Ravandi, Farhad; Döhner, Hartmut; Wei, Andrew H; Montesinos, Pau; Pfeilstöcker, Michael; Papayannidis, Cristina; Lai, Yinzhi; Wang, Kefeng; See, Wendy L; de Menezes, Daniel Lopes; Petrlik, Erica; Prebet, Thomas; Roboz, Gail J.
Affiliation
  • Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Döhner H; Ulm University Hospital, Ulm, Germany.
  • Wei AH; Peter MacCallum Cancer Centre, Melbourne, Australia.
  • Montesinos P; The Royal Melbourne Hospital, Melbourne, Australia.
  • Pfeilstöcker M; Hematology Department, Hospital Universitari i Politècnic, La Fe, València, Spain.
  • Papayannidis C; CIBERONC, Instituto Carlos III, Madrid, Spain.
  • Lai Y; Third Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna, Austria.
  • Wang K; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
  • See WL; IRCCS, Azienda Ospedaliero Universitaria di Bologna, Istituto di Ematologia "L. e A. Seràgnoli", Bologna, Italy.
  • de Menezes DL; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Petrlik E; Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Prebet T; Bristol Myers Squibb, San Francisco, California, USA.
  • Roboz GJ; Bristol Myers Squibb, San Francisco, California, USA.
Br J Haematol ; 204(3): 877-886, 2024 Mar.
Article in En | MEDLINE | ID: mdl-37952982

Full text: 1 Database: MEDLINE Main subject: Azacitidine / Leukemia, Myeloid, Acute Limits: Humans Language: En Journal: Br J Haematol Year: 2024 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Azacitidine / Leukemia, Myeloid, Acute Limits: Humans Language: En Journal: Br J Haematol Year: 2024 Type: Article Affiliation country: United States